Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes

• Published in: Future science OA 2022-03, Vol.8 (3), p.FSO779-FSO779
• Main Authors: Mosikian, Anna A, Golikova, Tatiana I, Martjanova, Mariia V, Babenko, Alina Y
• Format: Article
• Language: English
• Subjects: diabetes mellitus; glucagon-like peptide-1 receptor agonists; liraglutide; obesity; predictors
• ISSN: 2056-5623; 2056-5623
• DOI: 10.2144/fsoa-2021-0070

The effects of liraglutide on body weight and hemoglobin A1C (HbA1c) level vary greatly. The cost of this drug negatively affects treatment adherence. To reveal the baseline patient characteristics, associated with a better response to liraglutide.  A total of 41 patients with BMI of 39.63 ± 7.59 kg/m who received liraglutide injection up to 1.8 or 3.0 mg/day for 6 months were enrolled. Demographic and anthropometric data, parameters of glycemic control, food intake, hormones and responses to the eating behavior questionnaire were collected. Weight reduction was dose-dependent (p = 0.007). Liraglutide was not effective in patients with BMI >45 kg/m . The baseline HbA1c level was a significant factor for HbA1c reduction. Lower leptin and higher glucagon-like-peptide 1 concentrations might predict better weight loss response to liraglutide. Drug-specific efficacy predictors were assumed; thus, further studies are needed to prove their significance. The objective of this study was to identify the baseline patient characteristics as a predictors associated with a better response to liraglutide. It is related to different effect of liraglutide on body weight and hemoglobin A1c (HbA1c) in different patients. We found that weight reduction was dose-dependent (p = 0.007) and liraglutide was not effective in patients with BMI >45 kg/m . The baseline HbA1c level significantly correlated with HbA1c reduction. Lower leptin and higher glucagon-like peptide-1 concentrations might predict better weight loss response to liraglutide.